Sandy Macrae - Feb 24, 2024 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Signature
/s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
SGMO
Transactions as of
Feb 24, 2024
Transactions value $
-$45,507
Form type
4
Date filed
2/27/2024, 05:11 PM
Previous filing
Jan 24, 2024
Next filing
May 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SGMO Common Stock Tax liability -$18.2K -16.1K -0.62% $1.13 2.58M Feb 24, 2024 Direct F1, F2, F3
transaction SGMO Common Stock Tax liability -$27.3K -24.2K -0.94% $1.13 2.55M Feb 25, 2024 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying the portions of RSU grants that vested on February 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2 Includes: (a) 23,210 shares resulting from the February 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 117,975 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 46,134 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (c) 105,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (d) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter.
F3 The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F4 Represents shares underlying the portions of RSU grants that vested on February 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F5 Includes: (a) 29,280 shares resulting from the February 25, 2024 final vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 13,697 shares resulting from the February 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 84,000 shares will vest in successive equal quarterly installments through February 25, 2025, (c) 117,975 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (d) 2,000,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter.